CG Oncology (NASDAQ:CGON) Shares Up 18.3%

Shares of CG Oncology, Inc. (NASDAQ:CGON) rose 18.3% on Friday . The stock traded as high as $46.99 and last traded at $46.74. Approximately 100,653 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 607,582 shares. The stock had previously closed at $39.50.

Analysts Set New Price Targets

CGON has been the subject of several analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $75.00 target price on shares of CG Oncology in a research report on Thursday. The Goldman Sachs Group began coverage on shares of CG Oncology in a report on Tuesday, February 20th. They issued a “neutral” rating and a $42.00 target price on the stock. Morgan Stanley started coverage on shares of CG Oncology in a research note on Tuesday, February 20th. They set an “overweight” rating and a $55.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of CG Oncology in a research note on Thursday, April 4th.

CG Oncology Price Performance

The stock’s 50-day simple moving average is $39.78.

Institutional Trading of CG Oncology

An institutional investor recently bought a new position in CG Oncology stock. BNP Paribas Financial Markets purchased a new stake in CG Oncology, Inc. (NASDAQ:CGON) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 11,198 shares of the company’s stock, valued at approximately $492,000. Institutional investors own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.